Evidence map›Paper›PMID 35157943›Full record

ReviewDiabetes research and clinical practice2022

Delivering evidence-based interventions for type 1 diabetes in the virtual world - A review of UK practice during the SARS-CoV-2 pandemic.

A Sathyanarayanan, T Crabtree, P Choudhary, J Elliott, M L Evans, A Lumb, E G Wilmot

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diabetes research and clinical practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

A SathyanarayananUniversity Hospitals of Derby and Burton NHS FT, DE22 3NE, UK. Electronic address: abilash.sathya@nhs.net.
T CrabtreeUniversity Hospitals of Derby and Burton NHS FT, DE22 3NE, UK; Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, NG7 2RD, UK. Electronic address: t.crabtree@nhs.net.
P ChoudharyDiabetes Research Centre, Leicester Diabetes Centre - Bloom, University of Leicester, LE1 7RH, UK. Electronic address: pratik.choudhary@leicester.ac.uk.
J ElliottDepartment of Oncology and Metabolism, University of Sheffield, S10 2TN, UK. Electronic address: j.elliott@sheffield.ac.uk.
M L EvansWellcome Trust/ MRC Institute of Metabolic Science and Department of Medicine, University of Cambridge, CB2 1TN, UK. Electronic address: mle24@cam.ac.uk.
A LumbOxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford OX3 7LE, UK; NIHR Oxford Biomedical Research Centre, Oxford OX4 2PG, UK. Electronic address: alistair.lumb@ouh.nhs.uk.
E G WilmotUniversity Hospitals of Derby and Burton NHS FT, DE22 3NE, UK; Division of Medical Sciences & Graduate Entry Medicine, School of Medicine, University of Nottingham, NG7 2RD, UK.
University of Nottingham · GBChurchill Hospital · GBUniversity Hospitals of Derby and Burton NHS Foundation Trust · GBUniversity of Leicester · GBUniversity of Sheffield · GBWellcome/MRC Institute of Metabolic Science · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis review considers the impact of the SARS-CoV-2 pandemic on access to interventions for those living with type 1 diabetes and discusses the solutions which have been considered and actioned to ensure ongoing access care.

methodsWe performed a focussed review of the published literature, and the guidelines for changes that have been effected during the pandemic. We also drew from expert recommendations and information about local practice changes for areas where formal data have not been published.

resultsEvidence based interventions which support the achievement of improved glucose levels and/or reduction in hypoglycaemia include group structured education to support self-management, insulin pump therapy and continuous glucose monitoring. The SARS-CoV-2 pandemic had impacted the ability of diabetes services to deliver these intervention. Multiple adaptations have been put in place - transition to online delivery of education and care, and usage of diabetes technology.

conclusionsAlthough various adaptations have been made during the pandemic that have positively influenced uptake of services, there are many areas of delivery that need immediate improvement in the UK. We recommend a proactive approach in recognising the digital divide and inequity in distribution of these changes and we recommend introducing measures to reduce them.

Indexed as

COVID-19Diabetes Mellitus, Type 1Blood GlucoseBlood Glucose Self-MonitoringEvidence-Based MedicineHumansPandemicsSARS-CoV-2United KingdomBlood GlucoseBlood Glucose Self-MonitoringDiabetes MellitusDigital DivideQuality of LifeRemote ConsultationSARS-CoV-2Type 1

Identifiers

PMID35157943
PMCPMC8831709
OpenAlexW4210979309

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.